Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN7 | P35236 | 12/20 | 1.00 |
| ▸ | HSPA1A | P0DMV8 | 8/20 | 1.00 |
| ▸ | HSPA8 | P11142 | 6/20 | 1.00 |
| ▸ | GAPDH | P04406 | 5/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 5/20 | 0.74 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.74 |
| ▸ | MEN1 | O00255 | 4/20 | 0.74 |
| ▸ | POLB | P06746 | 4/20 | 0.74 |
| ▸ | MAPT | P10636 | 4/20 | 0.74 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.74 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.74 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.74 |
| ▸ | RECQL | P46063 | 3/20 | 0.74 |
| ▸ | BLM | P54132 | 3/20 | 0.74 |
| ▸ | THRB | P10828 | 2/20 | 0.74 |
| ▸ | CACNA1B | Q00975 | 2/20 | 0.74 |
| ▸ | APBA1 | Q02410 | 2/20 | 0.74 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.74 |
| ▸ | USP2 | O75604 | 1/20 | 0.74 |
| ▸ | GAA | P10253 | 1/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2116061 | 0.85 | PTPN7 (1.00) | PTPN7HSPA1AHSPA8GAPDHTDP1 | |
| SCHEMBL14758490 | 0.84 | CDC25B (1.00) | PTPN7HSPA1AHSPA8GAPDHTDP1 | |
| SCHEMBL2804418 | 0.84 | CDC25B (1.00) | PTPN7HSPA1AHSPA8GAPDHTDP1 | |
| SCHEMBL13726071 | 0.82 | PTPN7 (1.00) | PTPN7HSPA1AHSPA8GAPDHTDP1 | |
| SCHEMBL23949485 | 0.81 | PTPN7 (1.00) | PTPN7HSPA1AHSPA8GAPDHTDP1 | |
| SCHEMBL2117317 | 0.81 | PTPN7 (1.00) | PTPN7HSPA1AHSPA8GAPDHTDP1 | |
| SCHEMBL13856221 | 0.80 | NR4A1 (1.00) | PTPN7HSPA1AHSPA8GAPDHTDP1 | |
| SCHEMBL13856208 | 0.80 | NR4A1 (1.00) | PTPN7HSPA1AHSPA8GAPDHTDP1 | |
| SCHEMBL13726075 | 0.79 | CDC25B (0.76) | PTPN7HSPA1AHSPA8GAPDHTDP1 | |
| SCHEMBL13856742 | 0.79 | PTPN7 (1.00) | PTPN7HSPA1AHSPA8GAPDHTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10682359-B2 | Inhibitors of glucose kinases, along with methods of their formation and use | UNIVERSITY OF SOUTH CAROLINA (US) | 2020-06-16 | — | — | US | disclosed |
| US-10195213-B2 | Chemical entities that kill senescent cells for use in treating age-related disease | UNITY BIOTECHNOLOGY, INC. (US) | 2019-02-05 | — | — | US | disclosed |
| US-10000511-B2 | Small molecules for the modulation of MCL-1 and methods of modulating cell death, cell division, cell differentiation and methods of treating disorders | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2018-06-19 | — | — | US | disclosed |
| US-10000511-B2 | Small molecules for the modulation of MCL-1 and methods of modulating cell death, cell division, cell differentiation and methods of treating disorders | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2018-06-19 | — | — | US | disclosed |
| US-20170281649-A1 | COMPOUNDS AND THERAPEUTIC USES | UNITY BIOTECHNOLOGY, INC. | 2017-10-05 | — | — | US | disclosed |
| US-20170281649-A1 | COMPOUNDS AND THERAPEUTIC USES | UNITY BIOTECHNOLOGY, INC. | 2017-10-05 | — | — | US | disclosed |
| EP-3138838-A1 | SMALL MOLECULES FOR THE MODULATION OF MCL-1 AND METHODS OF MODULATING CELL DEATH, CELL DIVISION, CELL DIFFERENTIATION AND METHODS OF TREATING DISORDERS | Dana-Farber Cancer Institute, Inc. (US) | 2017-03-08 | — | — | EP | disclosed |
| US-20150315211-A1 | SMALL MOLECULES FOR THE MODULATION OF MCL-1 AND METHODS OF MODULATING CELL DEATH, CELL DIVISION, CELL DIFFERENTIATION AND METHODS OF TREATING DISORDERS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-11-05 | — | — | US | disclosed |
| US-20150315211-A1 | SMALL MOLECULES FOR THE MODULATION OF MCL-1 AND METHODS OF MODULATING CELL DEATH, CELL DIVISION, CELL DIFFERENTIATION AND METHODS OF TREATING DISORDERS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-11-05 | — | — | US | disclosed |
| US-20130035304-A1 | SMALL MOLECULES FOR THE MODULATION OF MCL-1 AND METHODS OF MODULATING CELL DEATH, CELL DIVISION, CELL DIFFERENTIATION AND METHODS OF TREATING DISORDERS | NATIONAL INSTITUTES OF HEALTH-DIRECTOR DEITR | 2013-02-07 | — | — | US | disclosed |
| US-20130035304-A1 | SMALL MOLECULES FOR THE MODULATION OF MCL-1 AND METHODS OF MODULATING CELL DEATH, CELL DIVISION, CELL DIFFERENTIATION AND METHODS OF TREATING DISORDERS | NATIONAL INSTITUTES OF HEALTH-DIRECTOR DEITR | 2013-02-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170281649-A1 | COMPOUNDS AND THERAPEUTIC USES | TP53, NQO1, SHMT2 | PTPN7 2529/4885HSPA1A 1072/4885HSPA8 1197/4885 |
| US-20130035304-A1 | SMALL MOLECULES FOR THE MODULATION OF MCL-1 AND METHODS OF MODULATING CELL DEATH, CELL DIVISION, CELL DIFFERENTIATION AND METHODS OF TREATING DISORDERS | MCL1, BCL2, BCL2L1 | PTPN7 3462/4885HSPA1A 515/4885HSPA8 715/4885 |
| US-10000511-B2 | Small molecules for the modulation of MCL-1 and methods of modulating cell death, cell division, cell differentiation and methods of treating disorders | MCL1, BCL2, BCL2L1 | PTPN7 3462/4885HSPA1A 515/4885HSPA8 715/4885 |
| US-20150315211-A1 | SMALL MOLECULES FOR THE MODULATION OF MCL-1 AND METHODS OF MODULATING CELL DEATH, CELL DIVISION, CELL DIFFERENTIATION AND METHODS OF TREATING DISORDERS | MCL1, BCL2, BCL2L1 | PTPN7 3462/4885HSPA1A 515/4885HSPA8 715/4885 |
| US-10195213-B2 | Chemical entities that kill senescent cells for use in treating age-related disease | TP53, CDKN1A, GLA | PTPN7 2149/4885HSPA1A 1036/4885HSPA8 1253/4885 |
| US-10682359-B2 | Inhibitors of glucose kinases, along with methods of their formation and use | GCK, GCKR, GALK1 | PTPN7 1836/4885HSPA1A 1509/4885HSPA8 1441/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.